CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways.
IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多因素扩增方案可在体外有效提高活化 CAR-T 细胞表面 CXCR3 的表达,并在体内增强 CAR-T 细胞的趋化能力,从而显著抑制肝癌生长。
肿瘤内高淋巴细胞浸润是肿瘤免疫治疗取得良好效果的基本要求;C-X-C基序趋化因子受体3(CXCR3)是淋巴细胞向肿瘤组织趋化的重要因子。肿瘤微环境可表现出多种细胞因子抑制或促进抗肿瘤免疫。白细胞介素(IL)-2和粒细胞巨噬细胞集落刺激因子(GM-CSF)均有助于调节肿瘤微环境中的免疫抑制。然而,IL-2和GM-CSF对T细胞表面CXCR3表达的影响及其机制尚不清楚。在此,我们探讨了多细胞因子对CAR-T 细胞(CAR-T 细胞)中CXCR3表达的影响以及对HuH-7原位肝细胞癌的影响。
探讨细胞因子IL-2和GM-CSF对CAR-T 细胞CXCR3表达及趋化作用的影响。
外周血单个核细胞(PBMCs)被分离,随后使用CD3免疫磁珠进行纯化。细胞分为三组。使用CD3/CD28抗体激活24小时后,T细胞使用慢病毒载体pGC-SV40-EGFP-GPC3-CAR进行转染。使用三种培养方法扩增转染的T细胞。方法“A”是将T细胞与CD3/CD28抗体共孵育;方法“B”是使用CD3/CD28抗体和终浓度为1000 U/ml的IL-2;方法“C”是在方法B的基础上添加终浓度为1000 U/ml的GM-CSF。通过western blot测定MAPK和PI3K/AKT的磷酸化。通过免疫荧光和免疫组化检测CAR-T 细胞对Huh-7 HCCIA原位的趋化作用。
CD3/CD28/IL-2/GM-CSF组合在体外对刺激活化的CAR-T 细胞增殖和CXCR3表达最为有效;CD3/CD28/IL-2通过激活PI3K/APK通路诱导CAR-T 细胞表达CXCR3,GM-CSF通过激活ERK1/2而非p38 MAPK信号通路诱导CAR-T 细胞中CXCR3的表达。CXCR3高表达的CAR-GPC3-T细胞对HuH原位肝细胞癌的趋化能力增强,并显著抑制裸鼠肝脏中原位肿瘤的生长。
To investigate the effects of cytokines IL-2 and GM-CSF on CXCR3 expression and chemotaxis of CAR-T cells.
High lymphocyte infiltration within the tumor is a basic requirement for good results in tumor immunotherapy; C-X-C motif chemokine receptor 3 (CXCR3) is an important factor for the chemotaxis of lymphocytes to tumor tissues. The tumor microenvironment can exhibit diverse cytokine suppression or promote antitumor immunity. Both interleukin (IL)-2 and granulocyte macrophage colony-stimulating factor (GM-CSF) contribute to the regulation of immunosuppression in the tumor microenvironment. However, the effects of IL-2 and GM-CSF on CXCR3 expression on the T cell surface and its mechanisms are not well understood. Here, we explored the effects of polycytokines on CXCR3 expression in chimeric antigen receptor T cells (CAR-T cells) and on HuH-7 in situ hepatocellular carcinoma.
Peripheral blood mononuclear cells (PBMCs) were isolated, followed by purifying using CD3 immunomagnetic beads. Cells were divided into three groups. After 24h of activation using CD3/CD28 antibody, T cells were transfected using lentiviral vector, pGC-SV40-EGFP-GPC3-CAR. Three culture methods were used to amplify the transfected T cells. Method 'A' was to incubate T cells with CD3/CD28 antibody; method 'B' was with CD3/CD28 antibody and IL-2 at a final concentration of 1000 U/ml; method 'C' was with method B in addition of GM-CSF at a final concentration of 1000 U/ml. The phosphorylation of MAPK and PI3K/AKT was determined by western blot. The chemotaxis effect of CAR-T cells on Huh-7 HCCIA in situ was assayed by immunofluorescence and immunohistochemistry.
The CD3/CD28/IL-2/GM-CSF combination is the most potent for stimulating activated CAR-T cell proliferation and CXCR3 expression in vitro; CD3/CD28/IL-2 induces CAR-T cell expression of CXCR3 through the activation of the PI3K/APK pathway and GM-CSF induces CXCR3 expression in CAR-T cells through the activation of ERK1/2 rather than the p38 MAPK signaling pathway. CAR-GPC3-T cells with high CXCR3 expression showed increased chemotaxis ability to HuH in situ hepatocellular carcinoma, and considerably inhibited the growth of in situ tumors in nude mouse livers.
A multi-factorial amplification protocol can effectively improve CXCR3 expression on the surface of activated CAR-T cells in vitro, as well as enhance the chemotaxis ability of CAR-T cells in vivo, which significantly inhibit the growth of liver cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。